Synonyms 一氧化氮合酶Ⅲ型, cNOS, Constitutive NOS + [11] |
Introduction Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway (PubMed:1378832). NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. |
Target |
Mechanism eNOS modulators |
Active Org. |
Originator Org. ![]() |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism EEF1A1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Mechanism 5-HT1B receptor agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date29 Feb 2024 |
Sponsor / Collaborator |
Start Date14 Feb 2022 |
Sponsor / Collaborator |
Start Date22 Nov 2021 |
Sponsor / Collaborator |